Latest Period
Q2 2026
Security Snapshot
Silence Therapeutics plc - Ordinary share, nominal value 0.05 GBP per share (SLN) Institutional Ownership
CUSIP: 82686Q101
13F Institutional Holders and Ownership History from Q3 2020 to Q2 2026
Institutions Reporting
69
Shares (Excl. Options)
21,351,214
Price
$10.98
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary share, nominal value 0.05 GBP per share
- Symbol
- SLN on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 21,351,214
- Total 13F value
- $234,407,432
- Portfolio coverage rank
- 0%
- Share change
- +2,435,737
- Value change
- +$29,227,164
- Number of holders
- 69
- Shares outstanding
- 141,918,771
- SEC-reported price per share
- $15.43
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- SLN - Silence Therapeutics plc - Ordinary share, nominal value 0.05 GBP per share is tracked under CUSIP 82686Q101.
- 69 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 54 to 69 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $100,349,336 to $234,407,432.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 69 institutions filings for Q2 2026.
Security key
82686Q101
Latest holder period
Q2 2026
13F holders
69
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
SLN full holder history
Silence Therapeutics plc SEC filings
Silence Therapeutics plc company facts
Silence Therapeutics plc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 82686Q101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
SLN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Invus Global Management, LLC | 7% | $90,302,914 | 9,934,314 | Raymond Debbane | 30 Jun 2026 |
As of 30 Jun 2026, 69 institutional investors reported holding 21,351,214 shares of Silence Therapeutics plc - Ordinary share, nominal value 0.05 GBP per share (SLN). This represents 15% of the company’s total 141,918,771 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
14%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Siren, L.L.C. | 2.3% | 3,311,438 | +14% | 0.74% | $36,359,589 |
| TCG Crossover Management, LLC | 2.1% | 3,033,560 | 0% | 0.8% | $33,308,489 |
| Redmile Group, LLC | 1.5% | 2,164,777 | 0% | 1.6% | $23,769,251 |
| Nantahala Capital Management, LLC | 0.95% | 1,346,731 | -37% | 0.89% | $14,787,106 |
| CITADEL ADVISORS LLC | 0.94% | 1,329,625 | +7.7% | 0.01% | $14,599,282 |
| Nextech Invest Ltd. | 0.67% | 952,400 | 0% | 0.5% | $10,457,352 |
| MILLENNIUM MANAGEMENT LLC | 0.64% | 909,279 | -15% | 0.01% | $9,983,883 |
| Tetragon Partners GP Ltd | 0.54% | 764,256 | +21% | 1.4% | $8,391,531 |
| Soleus Capital Management, L.P. | 0.44% | 630,000 | 0.24% | $6,917,400 | |
| Balyasny Asset Management L.P. | 0.43% | 610,980 | 0.01% | $6,708,560 | |
| 5AM Venture Management, LLC | 0.34% | 476,200 | 0% | 1.8% | $5,228,676 |
| GREAT POINT PARTNERS LLC | 0.32% | 450,000 | -56% | 1.2% | $4,941,000 |
| MORGAN STANLEY | 0.28% | 403,172 | +516% | 0% | $4,426,828 |
| AMERIPRISE FINANCIAL INC | 0.26% | 370,052 | 0% | $4,063,171 | |
| JANE STREET GROUP, LLC | 0.26% | 369,151 | +266% | 0% | $4,053,278 |
| ADAR1 Capital Management, LLC | 0.24% | 338,373 | +97% | 0.18% | $3,715,336 |
| SummitTX Capital, L.P. | 0.23% | 326,648 | 0.09% | $3,586,595 | |
| Schonfeld Strategic Advisors LLC | 0.19% | 269,348 | 0.02% | $2,957,439 | |
| UBS Group AG | 0.17% | 243,152 | -1.5% | 0% | $2,669,809 |
| BlackRock, Inc. | 0.15% | 219,917 | +7.4% | 0% | $2,414,689 |
| BANK OF MONTREAL /CAN/ | 0.14% | 201,734 | -0.58% | 0% | $2,215,039 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.14% | 198,347 | -5.1% | 0.04% | $2,177,850 |
| Propel Bio Management, LLC | 0.14% | 191,733 | 1.1% | $2,105,228 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.13% | 184,519 | +60% | 0% | $2,026,019 |
| FRED ALGER MANAGEMENT, LLC | 0.12% | 177,000 | 0.01% | $1,943,460 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Latest
Q2 2026
Rows shown
1-24 of 24
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 21,351,214 | $234,407,432 | +$29,227,164 | $10.98 | 69 |
| 2026 Q1 | 19,043,695 | $100,349,336 | +$6,469,716 | $5.27 | 54 |
| 2025 Q4 | 17,224,267 | $104,343,320 | -$7,839,973 | $6.08 | 56 |
| 2025 Q3 | 18,803,653 | $95,127,307 | -$511,345 | $5.19 | 53 |
| 2025 Q2 | 18,886,067 | $106,639,472 | -$14,651,806 | $5.80 | 54 |
| 2025 Q1 | 21,916,214 | $60,638,220 | -$13,764,100 | $2.82 | 58 |
| 2024 Q4 | 24,817,325 | $168,176,092 | -$84,640,277 | $6.88 | 64 |
| 2024 Q3 | 27,610,121 | $489,765,707 | -$39,911,094 | $18.18 | 68 |
| 2024 Q2 | 26,720,959 | $498,801,443 | -$26,369,400 | $19.00 | 70 |
| 2024 Q1 | 27,723,671 | $588,039,512 | +$167,294,837 | $21.60 | 64 |
| 2023 Q4 | 20,540,034 | $343,909,477 | +$16,816,242 | $17.37 | 34 |
| 2023 Q3 | 19,721,299 | $187,568,316 | +$5,649,221 | $9.82 | 28 |
| 2023 Q2 | 19,229,837 | $101,780,933 | +$4,398,940 | $5.50 | 29 |
| 2023 Q1 | 18,398,088 | $110,231,731 | -$8,695,579 | $6.20 | 29 |
| 2022 Q4 | 18,637,187 | $275,732,466 | +$658,683 | $15.25 | 27 |
| 2022 Q3 | 18,656,839 | $183,366,118 | +$81,713,433 | $10.03 | 29 |
| 2022 Q2 | 10,367,019 | $116,349,742 | -$33,812,496 | $11.85 | 24 |
| 2022 Q1 | 12,183,311 | $218,253,654 | +$13,309,267 | $19.00 | 25 |
| 2021 Q4 | 10,341,285 | $246,622,000 | +$171,435,669 | $23.89 | 21 |
| 2021 Q3 | 1,955,799 | $39,359,000 | -$5,425,406 | $20.61 | 7 |
| 2021 Q2 | 2,261,433 | $56,411,000 | -$6,759,832 | $25.78 | 6 |
| 2021 Q1 | 2,547,036 | $55,940,000 | +$44,883,639 | $23.01 | 6 |
| 2020 Q4 | 542,093 | $10,212,000 | +$2,000 | $21.51 | 3 |
| 2020 Q3 | 542,000 | $8,135,000 | +$8,135,000 | $15.50 | 2 |